表纸
市场调查报告书

糖尿病性末梢神经病变:全球临床实验趋势

Diabetic Peripheral Neuropathy Global Clinical Trials Review, H1, 2020

出版商 GlobalData 商品编码 302385
出版日期 内容资讯 英文
订单完成后即时交付
价格
糖尿病性末梢神经病变:全球临床实验趋势 Diabetic Peripheral Neuropathy Global Clinical Trials Review, H1, 2020
出版日期: 2020年06月04日内容资讯: 英文
简介

本报告提供糖尿病性末梢神经病变的治疗药相关临床实验最新趋势分析,以疾病概要为首,提供您各地区及主要国家的临床实验状况,各进展状况临床实验资料,受验者的募集情况,有潜力的赞助商,并汇整各企业·研究机关临床实验简介等资讯。

本报告概要

各地区的临床实验情形

  • 各国临床实验数量和平均实验人数
    • 亚太地区主要5国的临床实验数量
    • 欧洲主要5国的临床实验数量
    • 北美主要国家的临床实验数量
    • 中东·非洲主要5国的临床实验数量
    • 中南美主要5国的临床实验数量

G7各国临床实验数量:代谢异常治疗药临床实验上糖尿病性末梢神经病变的比例

G7各国的各阶段临床实验数量

G7各国临床实验数量:各进展状况

E7各国临床实验数量:代谢异常治疗药临床实验上糖尿病性末梢神经病变的比例

E7各国的各阶段临床实验数量

E7各国临床实验数量:各进展状况

各阶段临床实验数量

  • 进行中的临床实验:各阶段

各进展状况临床实验数量

临床实验的目标达成情形

一定期间所采用的实验对象

赞助商类别的临床实验数量

有潜力的赞助商

糖尿病性末梢神经病变治疗药临床实验主要的参与企业

有潜力的药剂

最新临床实验新闻

临床实验简介概要

附录

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GDHC6271CTIDB

GlobalData's clinical trial report, "Diabetic Peripheral Neuropathy Global Clinical Trials Review, H1, 2020" provides an overview of Diabetic Peripheral Neuropathy Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Peripheral Neuropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Diabetic Peripheral Neuropathy to Metabolic Disorders Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Diabetic Peripheral Neuropathy to Metabolic Disorders Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Diabetic Peripheral Neuropathy Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots

Appendix

  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About GlobalData
  • Contact Us
  • Source

List of Tables

List of Tables

  • Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Region, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Europe, Top Five Countries, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, North America, Top Countries, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2020*
  • Proportion of Diabetic Peripheral Neuropathy to Metabolic Disorders Clinical Trials, G7 Countries (%), 2020*
  • Diabetic Peripheral Neuropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Diabetic Peripheral Neuropathy to Metabolic Disorders Clinical Trials, E7 Countries (%), 2020*
  • Diabetic Peripheral Neuropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Phase, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials In Progress by Phase 2020*
  • Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019
  • Diabetic Peripheral Neuropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*

List of Figures

List of Figures

  • Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Region (%), 2020*
  • Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2020*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2020*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, North America, Top Countries (%), 2020*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2020*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2020*
  • Proportion of Diabetic Peripheral Neuropathy to Metabolic Disorders Clinical Trials, G7 Countries (%), 2020*
  • Diabetic Peripheral Neuropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Diabetic Peripheral Neuropathy to Metabolic Disorders Clinical Trials, E7 Countries (%), 2020*
  • Diabetic Peripheral Neuropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Phase (%), 2020*
  • Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials In Progress by Phase, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019
  • Diabetic Peripheral Neuropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2020*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*
  • GlobalData Methodology